Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Transcatheter Arterial Chemoembolization Combined With Lenvatinib Plus Cadonilimab for Resectable Hepatocellular Carcinoma: A Single-Arm Phase II Clinical Trial

NCT06569498 is registered in ClinicalTrials.gov with Fujian Provincial Hospital as lead sponsor.

NCT NCT06569498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06569498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Transcatheter Arterial Chemoembolization Combined With Lenvatinib Plus Cadonilimab for Resectable Hepatocellular Carcinoma: A Single-Arm Phase II Clinical Trial
Lead sponsor
Fujian Provincial Hospital
Phase
Observational
Overall status
Recruiting
Start date
September 30, 2024
Completion date
December 1, 2026
Enrollment
20 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

resectable hepatocellular carcinoma